Non-Opioid Drugs Market for Chronic Pain Management Poised to Grow at a Healthy Annualized Rate 40%
Tapish Dogra, the principal analyst, stated, "In order to address the growing concerns related to opioid abuse, various companies have come up with novel non-opioid alternatives. Presently, over 145 non-opioid product candidates are marketed / under evaluation across various stages of development for the management of chronic pain caused due to various clinical conditions."
The report presents opinions on several key aspects of the market. Among other elements, it includes:
1. A detailed assessment of the current market landscape of drugs being developed for the treatment of chronic pain, providing information on their respective developer(s)
2. An in-depth analysis of the product pipeline and developer companies, featuring [A] a mirror analysis highlighting the relative popularity of different disease indications based on the number of molecules available / under development for each indication and the number of companies involved, [B] a logo landscape of the various industry players involved in this domain, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large), [C] a heptagon representation highlighting the distribution of marketed and pipeline molecules based on their respective mechanisms of action, and [D] a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type.
3. An analysis highlighting the key unmet needs across chronic pain, featuring insights generated from data sourced from patient blogs, recent scientific publications, social media posts and the views of key opinion leaders expressed on various online platforms.
4. An elaborate discussion on lifecycle management strategies, describing how different companies are using various methods to prolong patent age and, thereby, expand marketing exclusivity in order to exploit the revenue generation potential of their proprietary products. The section also includes detailed case studies elaborating on diverse lifecycle management strategies of marketed drugs that are nearing patent expiry.
5. Comprehensive profiles of drugs that are in phase III of clinical development with information on developer companies (including location of headquarters and year of establishment)
6. A detailed assessment of the current market landscape of various devices that are being developed for chronic pain management, highlighting information on developer (size of company and location of headquarters)
7. An insightful 2X2 competitive analysis for the various devices, highlighting the most important products based on the modality of device, treatment requirement, type of device, and supplier power (based on size of employee base of the company). The chapter also includes profiles of devices that emerged as relatively superior (based on the analysis); each profile features details on the developer (location of headquarters and year of establishment)
8. An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (related to both technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements and others.
9. An analysis of investments made at various stages of product development;
Dogra further added, "The future holds significant promise for companies working to develop novel non-opioid therapeutics and pain management devices. In fact, drugs which have received / are expected to receive approval for the treatment of migraine by late 2018 / early 2019 are most likely to achieve blockbuster status in the future. Further, in terms of drug class, by 2025, the market share is likely to be distributed amongst anti-CGRP drugs (54%), followed by NGF inhibitors (20%) and calcium / sodium channel blockers (16%)."
The research covers detailed profiles and assesses service portfolios of the following companies:
1. 1st Order Pharmaceuticals
2. 4P Therapeutics
5. AcelRx Pharmaceuticals
8. Anavex Life Sciences
9. Araim Pharmaceuticals
10. AVACEN Medical
12. Boehringer Ingelheim
13. Cara Therapeutics
17. Eli Lilly
18. ELvations Medical
20. Iroko Pharmaceuticals
23. Par Pharmaceuticals
24. Sumitomo Dainippon Pharma
25. Theravance Biopharma
26. ViaTherm Therapeutics
27. Zydus Pharmaceuticals
28. Zynex Medical
For additional details, please visit
or email firstname.lastname@example.org